Chief Legal Officer

Director

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Institution	Shares	Value	Change
FMR	18,217,239	$3.9B	INCREASED
Vanguard	17,817,720	$3.8B	INCREASED
BlackRock	15,985,736	$3.5B	INCREASED
Primecap Management Co	15,154,606	$3.3B	INCREASED
State Street	7,344,327	$1.6B	INCREASED

Insider	Type	Shares	Value	Date
Michael Parini (Chief Legal Officer)	AWARD	7,405		2026-09-01
Lloyd Minor (Director)	SELL	593	$121K	2026-08-03

Member	Type	Amount	Date
Kevin Hern (Republican)	SALE	$1,001 - $15,000	2026-08-18
Kevin Hern (Republican)	SALE	$1,001 - $15,000	2026-08-17
Maria Elvira Salazar (Republican)	SALE	$15,001 - $50,000	2026-06-02

Biogen Inc. Common Stock (BIIB) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades

Recent Congressional Trades